* Daiichi Sankyo Co Ltd – first patient has been enrolled in
global phase 3 quantum-first study evaluating oral FLT3-ITD
inhibitor quizartinib
The post BRIEF-Daiichi Sankyo begins enrollment for late-stage trial testing Quizartinib in leukemia patients appeared first on NASDAQ.